Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | CTH | P32929 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL906585 | 0.83 | CTH (0.35) | GRM5HTR7HTR1ADRD2HTR2A | |
| SCHEMBL29444546 | 0.83 | CTH (0.35) | GRM5HTR7HTR1ADRD2HTR2A | |
| SCHEMBL1041388 | 0.83 | HTR7 (0.33) | GRM5HTR7HTR1ADRD2HTR2A | |
| SCHEMBL21296390 | 0.80 | GABRA1 (0.34) | HTR7HTR1ADRD2HTR2A | |
| SCHEMBL5646151 | 0.79 | GABRA1 (0.36) | GRM5HTR7HTR1ADRD2HTR2A | |
| SCHEMBL957932 | 0.79 | SMN1; SMN2 (0.43) | GRM5HTR7HTR1ADRD2HTR2A | |
| SCHEMBL534247 | 0.79 | HTR7 (0.35) | GRM5HTR7HTR1ADRD2HTR2A | |
| SCHEMBL2757632 | 0.79 | HTR7 (0.35) | GRM5HTR7HTR1ADRD2HTR2A | |
| SCHEMBL29427057 | 0.79 | HTR7 (0.35) | GRM5HTR7HTR1ADRD2HTR2A | |
| SCHEMBL20910015 | 0.78 | CCR1 (0.43) | GRM5IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2017278-B1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD KK (JP) | 2016-11-02 | — | — | EP | disclosed |
| US-20140303178-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | MSD KK (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8791125-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2014-07-29 | — | — | US | disclosed |
| US-20110189130-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | SAGARA TAKESHI | 2011-08-04 | — | — | US | disclosed |
| US-7935708-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-7834019-B2 | Substituted pyrazolo[3,4-d]pyrimidinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| EP-2016080-B1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | MERCK SHARP & DOHME LLC | 2010-03-11 | — | — | US | disclosed |
| EP-2016080-A4 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2009-05-13 | — | — | EP | disclosed |
| EP-2016080-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-2017278-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007126122-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-11-08 | — | — | WO | disclosed |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189130-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE1, WEE2, GRK3 | GRM5 1337/4885HTR7 2297/4885HTR1A 1237/4885 |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | WEE1, WEE2, GRK3 | GRM5 1337/4885HTR7 2297/4885HTR1A 1237/4885 |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | WEE1, WEE2, GRK3 | GRM5 1337/4885HTR7 2297/4885HTR1A 1237/4885 |
| US-20140303178-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE1, WEE2, GRK3 | GRM5 1337/4885HTR7 2297/4885HTR1A 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.